These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 37170899)

  • 1. Therapies for acute myeloid leukemia in patients ineligible for standard induction chemotherapy: a systematic review.
    Heuser M; Fernandez C; Hauch O; Klibanov OM; Chaudhary T; Rives V
    Future Oncol; 2023 Apr; 19(11):789-810. PubMed ID: 37170899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Costs per patient achieving remission with venetoclax-based combinations in newly diagnosed patients with acute myeloid leukemia ineligible for intensive induction chemotherapy.
    Choi M; Song J; Bui CN; Ma E; Chai X; Yin L; Betts KA; Kapustyan T; Montez M; LeBlanc TW
    J Manag Care Spec Pharm; 2022 Sep; 28(9):980-988. PubMed ID: 35708343
    [No Abstract]   [Full Text] [Related]  

  • 3. Retrospective, real-life study of venetoclax plus azacitidine or low-dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy.
    Laloi L; Billotey NC; Dumas PY; Paul F; Villate A; Simand C; Fornecker L; Puisset F; Bertoli S; Simonet MB; Laribi K; Houyou D; Santagostino A; Michel C; Guepin GR; Guerineau E; Tabrizi R; Hunault M; Giltat A; Kaphan E; Bulabois C; Cartet E; Rocher C; Lachenal F; Morisset S; Récher C; Pigneux A; Belhabri A; Michallet M; Michallet AS
    Cancer Med; 2023 Mar; 12(6):7175-7181. PubMed ID: 36482507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Venetoclax combined with hypomethylating agents or low-dose cytarabine as induction chemotherapy for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review and meta-analysis.
    Qin Y; Kuang P; Liu T
    Clin Exp Med; 2023 Jun; 23(2):219-227. PubMed ID: 35066728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis.
    Agarwal S; Gopalakrishnan S; Mensing S; Potluri J; Hayslip J; Kirschbrown W; Friedel A; Menon R; Salem AH
    Hematol Oncol; 2019 Oct; 37(4):464-473. PubMed ID: 31251400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cost-effectiveness of glasdegib in combination with low-dose cytarabine, for the treatment of newly diagnosed acute myeloid leukemia in adult patients who are not eligible to receive intensive induction chemotherapy in Canada.
    Hu Y; Charaan M; van Oostrum I; Heeg B; Bell T
    J Med Econ; 2021; 24(1):150-161. PubMed ID: 33461352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial.
    Wei AH; Montesinos P; Ivanov V; DiNardo CD; Novak J; Laribi K; Kim I; Stevens DA; Fiedler W; Pagoni M; Samoilova O; Hu Y; Anagnostopoulos A; Bergeron J; Hou JZ; Murthy V; Yamauchi T; McDonald A; Chyla B; Gopalakrishnan S; Jiang Q; Mendes W; Hayslip J; Panayiotidis P
    Blood; 2020 Jun; 135(24):2137-2145. PubMed ID: 32219442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of venetoclax-based combination therapy for previously untreated acute myeloid leukemia: a meta-analysis.
    He H; Wen X; Zheng H
    Hematology; 2024 Dec; 29(1):2343604. PubMed ID: 38703055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study.
    Wei AH; Strickland SA; Hou JZ; Fiedler W; Lin TL; Walter RB; Enjeti A; Tiong IS; Savona M; Lee S; Chyla B; Popovic R; Salem AH; Agarwal S; Xu T; Fakouhi KM; Humerickhouse R; Hong WJ; Hayslip J; Roboz GJ
    J Clin Oncol; 2019 May; 37(15):1277-1284. PubMed ID: 30892988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-agent and combination biologics in acute myeloid leukemia.
    Richard-Carpentier G; DiNardo CD
    Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):548-556. PubMed ID: 31808888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world treatment patterns and clinical outcomes in patients with AML unfit for first-line intensive chemotherapy
    Miyamoto T; Sanford D; Tomuleasa C; Hsiao HH; Olivera LJE; Enjeti AK; Gimenez Conca A; Castillo TBD; Girshova L; Martelli MP; Guvenc B; Delgado A; Duan Y; Garbayo Guijarro B; Llamas C; Lee JH
    Leuk Lymphoma; 2022 Apr; 63(4):928-938. PubMed ID: 35147482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach.
    Boddu PC; Kantarjian HM; Ravandi F; Garcia-Manero G; Verstovsek S; Jabbour EJ; Takahashi K; Bhalla K; Konopleva M; DiNardo CD; Ohanian M; Pemmaraju N; Jain N; Pierce S; Wierda WG; Cortes JE; Kadia TM
    Cancer; 2017 Aug; 123(16):3050-3060. PubMed ID: 28387922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Venetoclax exposure-efficacy and exposure-safety relationships in patients with treatment-naïve acute myeloid leukemia who are ineligible for intensive chemotherapy.
    Brackman D; Eckert D; Menon R; Salem AH; Potluri J; Smith BD; Wei AH; Hayslip J; Miles D; Mensing S; Gopalakrishnan S; Zha J
    Hematol Oncol; 2022 Apr; 40(2):269-279. PubMed ID: 35043428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Venetoclax for the treatment of elderly or chemotherapy-ineligible patients with acute myeloid leukemia: a step in the right direction or a game changer?
    Agarwal S; Kowalski A; Schiffer M; Zhao J; Bewersdorf JP; Zeidan AM
    Expert Rev Hematol; 2021 Feb; 14(2):199-210. PubMed ID: 33459064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia.
    Kadia TM; Reville PK; Wang X; Rausch CR; Borthakur G; Pemmaraju N; Daver NG; DiNardo CD; Sasaki K; Issa GC; Ohanian M; Montalban-Bravo G; Short NJ; Jain N; Ferrajoli A; Bhalla KN; Jabbour E; Takahashi K; Malla R; Quagliato K; Kanagal-Shamanna R; Popat UR; Andreeff M; Garcia-Manero G; Konopleva MY; Ravandi F; Kantarjian HM
    J Clin Oncol; 2022 Nov; 40(33):3848-3857. PubMed ID: 35704787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An evaluation of venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine as therapy for acute myeloid leukemia.
    Othman TA; Tenold ME; Moskoff BN; Azenkot T; Jonas BA
    Expert Rev Hematol; 2021 May; 14(5):407-417. PubMed ID: 34076549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A quality-adjusted survival time without symptoms or toxicities analysis of glasdegib plus low-dose cytarabine versus low-dose cytarabine as initial therapy for acute myeloid leukemia in patients who are not considered candidates for intensive chemotherapy.
    Solem CT; Bell TJ; Kwon Y; Cappelleri JC; Johnson C; Bhattacharyya H; Hoang CJ; Cortes JE
    Cancer; 2020 Oct; 126(19):4315-4321. PubMed ID: 32697335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy.
    Richard-Carpentier G; DiNardo CD
    Ther Adv Hematol; 2019; 10():2040620719882822. PubMed ID: 31692757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Efficacy of Venetoclax-Based Combination Therapies and Other Therapies in Treatment-Naive Patients With Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy: A Network Meta-Analysis.
    Li X; Suh HS; Lachaine J; Schuh AC; Pratz K; Betts KA; Song J; Dua A; Bui CN
    Value Health; 2023 Dec; 26(12):1689-1696. PubMed ID: 37741447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary AML Emerging After Therapy with Hypomethylating Agents: Outcomes, Prognostic Factors, and Treatment Options.
    Richardson DR; Green SD; Foster MC; Zeidner JF
    Curr Hematol Malig Rep; 2021 Feb; 16(1):97-111. PubMed ID: 33609248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.